Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies

被引:9
|
作者
Dong, Lei [1 ]
Zhai, Xiao-Ying [2 ]
Yang, Yi-Lei [3 ]
Wang, Li [2 ]
Zhou, Yue [4 ]
Shi, Hai-Yan [3 ]
Tang, Bo-Hao [4 ]
Wu, Yue-E [4 ]
Yang, Fan [4 ]
Wen, Li [2 ]
Kong, Hong-Xiao [2 ]
Zhi, Li-Juan [1 ]
Jacqz-Aigrain, Evelyne [5 ,6 ]
Zhao, Wei [4 ,7 ]
机构
[1] Childrens Hosp Hebei Prov, Dept Pharm, Shijiazhuang, Hebei, Peoples R China
[2] Childrens Hosp Hebei Prov, Dept Paediat Haematol Oncol, Shijiazhuang, Hebei, Peoples R China
[3] Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Pharm, Jinan, Shandong, Peoples R China
[4] Shandong Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Jinan, Shandong, Peoples R China
[5] Hop Robert Debre, APHP, Dept Paediat Pharmacol & Pharmacogenet, Paris, France
[6] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France
[7] Childrens Hosp Hebei Prov, Paediat Res Inst, Shijiazhuang, Hebei, Peoples R China
关键词
children; dosing; imipenem; population pharmacokinetics; CRITICALLY-ILL PATIENTS; CLINICAL-EVALUATION; IMIPENEM/CILASTATIN; CILASTATIN; INFECTIONS; MEROPENEM; SURVEILLANCE; VANCOMYCIN; PNEUMONIA; PATTERNS;
D O I
10.1128/AAC.00006-19
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Imipenem is widely used for the treatment of children with serious infections. Currently, studies on the pharmacokinetics of imipenem in children with hematological malignancies are lacking. Given the significant impact of disease on pharmacokinetics and increased resistance, we aimed to conduct a population pharmacokinetic study of imipenem and optimize the dosage regimens for this vulnerable population. After children were treated with imipenem-cilastatin (IMP-CS), blood samples were collected from the children and the concentrations of imipenem were quantified using high-performance liquid chromatography with UV detection. Then, a population-level pharmacokinetic analysis was conducted using NONMEM software. Data were collected from 56 children (age range, 2.03 to 11.82 years) with hematological malignancies to conduct a population pharmacokinetic analysis. In this study, a two-compartment model that followed first-order elimination was found to be the most suitable. The parameters of current weight, age, and creatinine elimination rate were significant covariates that influenced imipenem pharmacokinetics. As a result, 41.4%, 56.1%, and 67.1% of the children reached the pharmacodynamic target (the percentage of the time during the total dosing interval that the free drug concentration remains above the MIC of 70%) against sensitive pathogens with an MIC of 0.5 mg/liter with imipenem at 15, 20, and 25 mg/kg of body weight every 6 h (q6h), respectively. However, only 11.1% of the children achieved the pharmacodynamic target against Pseudomonas aeruginosa isolates with an MIC of 2 mg/liter at a dose of 25 mg/kg q6h. The population pharmacokinetics of imipenem were assessed in children. The current dosage regimens of imipenem result in underdosing against resistant pathogens, including Pseudomonas aeruginosa and Acinetobacter baumannii. However, for sensitive pathogens, imipenem has an acceptable pharmacodynamic target rate at a dosage of 25 mg/kg q6h.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Population Pharmacokinetics and Dosing Optimization of Vancomycin in Children with Malignant Hematological Disease
    Zhao, Wei
    Zhang, Daolun
    Fakhoury, May
    Fahd, Mony
    Duquesne, Frederique
    Storme, Thomas
    Baruchel, Andre
    Jacqz-Aigrain, Evelyne
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (06) : 3191 - 3199
  • [2] PHARMACOKINETICS OF IMIPENEM CILASTATIN IN NEUTROPENIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
    JANMOHAMED, RMI
    LEYLAND, MJ
    KELLY, J
    FARRELL, I
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 (03) : 407 - 412
  • [3] Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients
    Bai, Jing
    Wen, Aiping
    Li, Zhe
    Li, Xingang
    Duan, Meili
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024, 31 (05) : 434 - 439
  • [4] Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection
    Zhi, Li-Juan
    Wang, Li
    Chen, Xing-Kai
    Zhai, Xiao-Ying
    Wen, Li
    Dong, Lei
    Jacqz-Aigrain, Evelyne
    Shi, Zhong-Ren
    Zhao, Wei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 855 - 862
  • [5] Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children
    Wang, Yang
    Sun, Dan
    Mei, Yan
    Wu, Sanlan
    Li, Xinlin
    Li, Sichan
    Wang, Jun
    Gao, Liuliu
    Xu, Hua
    Tuo, Yali
    PHARMACEUTICS, 2022, 14 (05)
  • [6] Population Pharmacokinetics of Teicoplanin and Its Dosing Recommendations for Neutropenic Patients With Augmented Renal Clearance for Hematological Malignancies
    Sako, Ken-ichi
    Nakamaru, Yuta
    Ikawa, Kazuro
    Maeda, Tomoji
    Goto, Sotaro
    Ishihara, Yoko
    Kato, Yukio
    Matsuda, Yoshikazu
    THERAPEUTIC DRUG MONITORING, 2021, 43 (04) : 519 - 526
  • [7] Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease
    Zhao, Wei
    Zhang, Daolun
    Storme, Thomas
    Baruchel, Andre
    Decleves, Xavier
    Jacqz-Aigrain, Evelyne
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (05) : 1197 - 1207
  • [8] Developmental population pharmacokinetics-pharmacodynamics and dosing optimization of cefoperazone in children
    Shi, Hai-Yan
    Wang, Kai
    Wang, Rong-Hua
    Wu, Yue-E
    Tang, Bo-Hao
    Li, Xue
    Du, Bin
    Kan, Min
    Zheng, Yi
    Xu, Bao-Ping
    Shen, A-Dong
    Su, Le-Qun
    Jacqz-Aigrain, Evelyne
    Huang, Xin
    Zhao, Wei
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (07) : 1917 - 1924
  • [9] Dosage optimization of voriconazole in children with haematological malignancies based on population pharmacokinetics
    Wu, Yun
    Lv, Chunle
    Wu, Dongni
    Qi, Jianying
    Cai, Rongda
    Zhou, Siru
    Li, Chengxin
    Wei, Yinyi
    Liu, Taotao
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (12) : 2245 - 2254
  • [10] Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies
    John David Clements
    Min Zhu
    Mita Kuchimanchi
    Bianca Terminello
    Sameer Doshi
    Clinical Pharmacokinetics, 2020, 59 : 463 - 474